Moxifloxacin Treatment for Bacterial Conjunctivitis

Efficacy and Resistance

Moxifloxacin has better coverage of gram-positive pathogens compared to earlier generation fluoroquinolones in head-to-head in vitro studies, according to the American Academy of Ophthalmology 1
Increasing resistance to fluoroquinolones has been observed, with risk factors including recent fluoroquinolone use, hospitalization, and recent ocular surgery, as reported by the Centers for Disease Control and Prevention 1
A 20-year study showed increasing overall resistance to moxifloxacin from 1996 to 2015, highlighting the need for alternative treatment options, as recommended by the Infectious Diseases Society of America 1
Moxifloxacin is generally poorly effective against methicillin-resistant Staphylococcus aureus (MRSA) ocular isolates, according to the American Academy of Ophthalmology 1

For suspected MRSA conjunctivitis, consider alternative agents like vancomycin as fluoroquinolones are generally poorly effective against MRSA ocular isolates, as recommended by the American Academy of Ophthalmology 1, 2
For resistant Pseudomonas aeruginosa, topical colistin 0.19% may be considered, according to the Infectious Diseases Society of America 2
For gonococcal conjunctivitis, systemic antibiotic therapy is necessary in addition to topical treatment, as recommended by the Centers for Disease Control and Prevention 2

If no improvement is seen after 7 days of treatment, reevaluation of diagnosis and treatment should be considered, as recommended by the American Academy of Ophthalmology 2, 3

The American Academy of Ophthalmology recommends Levofloxacin 1.5% as an FDA-approved alternative for bacterial conjunctivitis treatment, with demonstrated equal efficacy to ofloxacin 0.3% but superior microbiological eradication rates 4
Ciprofloxacin 0.3% and Ofloxacin 0.3% are FDA-approved but older generation fluoroquinolones with inferior gram-positive coverage 4

The Centers for Disease Control and Prevention notes that Methicillin-resistant Staphylococcus aureus (MRSA) is generally poorly effective against fluoroquinolones, including moxifloxacin, with methicillin resistance found in 42% of Staphylococcal isolates 4
The American Academy of Ophthalmology reports a sharp increase in Pseudomonas aeruginosa resistance to moxifloxacin in southern India, from 19% in 2007 to 52% in 2009 5
Recent fluoroquinolone use, recent hospitalization, and recent ocular surgery are risk factors for fluoroquinolone resistance 4